A5048037057- Immunotherapy and Immune Responses
- RNA Interference and Gene Delivery
- Extracellular vesicles in disease
- Epigenetics and DNA Methylation
- MicroRNA in disease regulation
- Cancer Genomics and Diagnostics
- Monoclonal and Polyclonal Antibodies Research
- RNA modifications and cancer
- Cancer-related gene regulation
- Cancer, Lipids, and Metabolism
- Chronic Lymphocytic Leukemia Research
- HER2/EGFR in Cancer Research
- Chronic Myeloid Leukemia Treatments
- Cancer Cells and Metastasis
- Genomics and Chromatin Dynamics
- Chromatin Remodeling and Cancer
- FOXO transcription factor regulation
- Hematopoietic Stem Cell Transplantation
- Wnt/β-catenin signaling in development and cancer
- Cancer Mechanisms and Therapy
- Click Chemistry and Applications
- Cell death mechanisms and regulation
- T-cell and B-cell Immunology
- Cancer Treatment and Pharmacology
- Ubiquitin and proteasome pathways
University of Southern California
2007-2022
City of Hope
2018
Children's Hospital of Los Angeles
2007-2011
Exosomes are naturally occurring membranous vesicles secreted by various types of cells. Given their unique and important biological pharmacological properties, exosomes have been emerging as a promising form nanomedicine acting via efficient delivery endogenous exogenous therapeutics. Here we explore new concept utilizing endogenously derived artificial controllers cellular immunity to redirect activate cytotoxic T cells toward cancer for killing. This was achieved through genetically...
Exosomes are nanosized membranous vesicles secreted by a variety of cells. Due to their unique and pharmacologically important properties, cell-derived exosome nanoparticles have drawn significant interest for drug development. By genetically modifying exosomes with two distinct types surface-displayed monoclonal antibodies, we developed an platform termed synthetic multivalent antibodies retargeted (SMART-Exo) controlling cellular immunity. Here, apply this approach human epidermal growth...
Exosomes are cell-derived nanovesicles involved in regulating intercellular communications. In contrast to conventional nanomedicines, exosomes characterized by unique advantages for therapeutic development. Despite their major successes drug delivery, the full potential of immunotherapy remains untapped. Herein we designed genetically engineered featured with surfaced-displayed antibody targeting groups and immunomodulatory proteins. Through genetic fusions exosomal membrane proteins,...
Background: Triple negative breast cancers (TNBCs) are an aggressive BC subtype, characterized by high rates of drug resistance and a proportion cancer stem cells (CSC). CSCs thought to be responsible for tumor initiation resistance. cAMP-response element-binding (CREB) binding protein (CREBBP or CBP) has been implicated in CSC biology may provide novel therapeutic target TNBC. Methods: RNA Seq pre- post treatment with the CBP-binding small molecule ICG-001 was used characterize CBP-driven...
A new approach is developed for generating site-specific antibody-drug conjugates targeted therapy.
The structure of oncogenic LMTK3 determines its role and functions allowing drug inhibition as a new therapeutic strategy.
Histone modification is aberrantly regulated in cancer and generates an unbalanced state of gene transcription. VprBP, a recently identified kinase, phosphorylates histone H2A on threonine 120 (T120) involved oncogenic transcriptional dysregulation; however, its specific role colon undefined. Here, we show that VprBP overexpressed directly contributes to epigenetic silencing pathogenesis. Mechanistically, the observed function mediated through H2AT120 phosphorylation (H2AT120p)‐driven...
We used magnetic resonance spectroscopy to determine whether orthotopic mouse brain tumors grown as xenografts in immunocompromised mice either from human tumor cells implanted immediately after surgery or cultured lines show metabolic profiles comparable those of the original tumors. Using a 7 T scanner, spectra were acquired with atypical teratoid/rhabdoid (AT/RT) directly surgical specimen first culture, choroid plexus carcinoma (CPC), and two medulloblastoma cell lines. The results...
Background and Objective: The development of the tyrosine kinase inhibitor Imatinib (IM) represents a milestone in CML (Chronic Myeloid Leukemia) treatment. However, it is not curative patients develop IM resistance. resistance has been previously correlated with emergence drug-resistant LIC/LSC (Leukemia Initiating Cell/Leukemia Stem Cell) increased nuclear catenin levels enhanced Wnt signaling. It demonstrated that drug resistant can be safely eliminated both vitro vivo via disruption...
There is currently no FDA approved therapeutic agent for ARS mitigation post radiation exposure. Here we report that the small molecule YH250, which specifically antagonizes p300/catenin interaction, stimulates hematopoiesis in lethally or sublethally irradiated mice. A single administration of YH250 24 hours irradiation can significantly stimulate HSC proliferation, improve survival and accelerate peripheral blood count recovery. Our studies suggest promotion expansion remaining population...
Abstract Liver cancer is one of the most common malignant tumors. It reported to be third lethal malignancy worldwide. Recent studies including our own identified CD133+ cell population as tumor initiating cells for liver cancer. Tumor suppressor PTEN (phosphatase and tensin homologue deleted on chromosome ten) aberrantly expressed in cancers. specific Pten (Pm) null mice develop following an extensive phase chronic lipid accumulation demonstrate escalating levels hepatic injury markers from...
Abstract Wnt/beta-catenin signaling plays an important role in the regulation of cell proliferation and differentiation, maintenance stem pluripotency cancer development. Using specific small molecular inhibitors, we have previously demonstrated that critical mechanism differentiating between differentiation is switch beta-catenin binding to coactivator CBP or p300 respectively. In colorectal cancer, hematologic malignancies with overt wnt/beta-catenin activity, inhibitor CBP/beta-catenin...